Goldman Sachs agreed to invest $150m in Biocon Biologics, a biopharmaceutical company, at a $3.9bn valuation. "We are extremely pleased to welcome a capital injection by Goldman Sachs at this inflection point of Biocon Biologics’ journey in its quest for global leadership in providing affordable access through Biosimilar drugs. This transaction is a part of the overall strategic plan of value creation for our shareholders through Biocon Biologics,” Kiran Mazumdar-Shaw, Biocon Executive Chairman.